On the stock market since 2021, it operates in the world of health and science. It has 138 employees. Now — the numbers.
The company is still in the product-building phase: its spending runs far above its sales. That only changes once the product starts selling at scale.
That much dependence is a risk in itself: if this one line weakens, the whole company feels it directly.
Before the clock runs out, either sales must climb sharply or new money must come in. For now, time is on the company’s side.
angles, checked one by one.
The 2 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
An investor who bought at the very peak is down 76% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
Sales run at $7.7M a year. A small number, but proof the product has real buyers.
There is $74.5M in the vault; even if every debt were paid off, $68.3M would remain.
It met or beat analyst expectations in 8 of the last 8 quarters — consistency is a promise kept.
A loss of $17.6M against $7.7M in annual sales.
On our five-subject report card, ADAG sits in the middle of the class: some subjects shine, others don’t. The grade moves as the numbers move.
The takeaway: ADAG is a high-risk stock — not yet profitable, and its future rides on its product catching on.